Innovative Alzheimer's combination therapy trial supported by new joint funding initiative

(Alzheimer's Association) The Alzheimer's Association and Alzheimer's Drug Discovery Foundation (ADDF) are collaborating to jointly fund a new combination therapy clinical trial for Alzheimer's disease to be conducted by Amylyx Pharmaceuticals. The $1.85 million grant is the first award under an initiative created by the Alzheimer's Association and the ADDF to fund combination therapies.

from EurekAlert! - Social and Behavioral Science http://ift.tt/2zL3gX8